Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAF1 | P04049 | 14/20 | 0.82 |
| ▸ | KDR | P35968 | 5/20 | 0.74 |
| ▸ | RET | P07949 | 4/20 | 0.74 |
| ▸ | BRAF | P15056 | 4/20 | 0.74 |
| ▸ | ABL1 | P00519 | 3/20 | 0.74 |
| ▸ | EPHA2 | P29317 | 3/20 | 0.74 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.74 |
| ▸ | MAP3K20 | Q9NYL2 | 3/20 | 0.74 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.74 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.74 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.74 |
| ▸ | HTR1A | P08908 | 2/20 | 0.74 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.74 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.74 |
| ▸ | KIT | P10721 | 2/20 | 0.74 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.74 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.74 |
| ▸ | FLT1 | P17948 | 2/20 | 0.74 |
| ▸ | MAOA | P21397 | 2/20 | 0.74 |
| ▸ | EPHA1 | P21709 | 2/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5086313 | 0.92 | RAF1 (0.87) | RAF1KDRRETBRAFABL1 | |
| SCHEMBL5082237 | 0.90 | RAF1 (0.83) | RAF1KDRRETBRAFABL1 | |
| SCHEMBL549001 | 0.90 | RAF1 (1.00) | RAF1KDRRETBRAFABL1 | |
| SCHEMBL1506322 | 0.88 | RAF1 (0.78) | RAF1KDRRETBRAFABL1 | |
| SCHEMBL1506420 | 0.87 | RAF1 (0.86) | RAF1KDRRETBRAFABL1 | |
| Regorafenib SCHEMBL29349808 | 0.85 | RAF1 (1.00) | RAF1KDRRETBRAFABL1 | |
| Regorafenib SCHEMBL29351376 | 0.85 | RAF1 (1.00) | RAF1KDRRETBRAFABL1 | |
| Regorafenib SCHEMBL432230 | 0.85 | RAF1 (1.00) | RAF1KDRRETBRAFABL1 | |
| SCHEMBL620651 | 0.85 | RAF1 (0.84) | RAF1KDRRETBRAFABL1 | |
| Sorafenib SCHEMBL8218 | 0.85 | RAF1 (1.00) | RAF1KDRRETBRAFABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210113614-A1 | COMBINATION OF CELLULAR IMMUNOTHERAPY | CARSGEN THERAPEUTICS CO., LTD. (CN) | 2021-04-22 | — | — | US | claimed |
| EP-3747433-A1 | COMBINATION OF CELLULAR IMMUNOTHERAPY | Carsgen Therapeutics Co., Ltd. (CN) | 2020-12-09 | — | — | EP | claimed |
| EP-1636585-B2 | DIARYL UREAS WITH KINASE INHIBITING ACTIVITY | BAYER HEALTHCARE LLC (US) | 2012-06-13 | — | — | EP | claimed |
| EP-2298311-B1 | w-Carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors | BAYER HEALTHCARE LLC (US) | 2012-05-09 | — | — | EP | claimed |
| EP-1158985-B1 | OMEGA-CARBOXY ARYL SUBSTITUTED DIPHENYL UREAS AS p38 KINASE INHIBITORS | BAYER HEALTHCARE LLC (US) | 2011-12-28 | — | — | EP | claimed |
| EP-2298311-A1 | w-Carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors | Bayer Healthcare Llc (US) | 2011-03-23 | — | — | EP | claimed |
| EP-1158985-A4 | OMEGA-CARBOXY ARYL SUBSTITUTED DIPHENYL UREAS AS p38 KINASE INHIBITORS | BAYER PHARMACEUTICALS CORP (US) | 2008-03-12 | — | — | EP | claimed |
| EP-1636585-B1 | DIARYL UREAS WITH KINASE INHIBITING ACTIVITY | BAYER PHARMACEUTICALS CORP (US) | 2008-01-16 | — | — | EP | claimed |
| EP-1626714-B1 | DIARYL UREAS FOR DISEASES MEDIATED BY PDGFR | BAYER PHARMACEUTICALS CORP (US) | 2007-07-04 | — | — | EP | claimed |
| JP-2007511203-A | — | — | 2007-05-10 | — | — | JP | claimed |
| US-20020042517-A1 | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors | BAYER CORPORATION | 2002-04-11 | — | — | US | claimed |
| EP-1158985-A1 | OMEGA-CARBOXY ARYL SUBSTITUTED DIPHENYL UREAS AS p38 KINASE INHIBITORS | Bayer Corporation (US) | 2001-12-05 | — | — | EP | claimed |
| US-20010034447-A1 | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors | BAYER HEALTHCARE LLC | 2001-10-25 | — | — | US | claimed |
| EP-1140840-A1 | -G(V)-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS | Bayer Corporation (US) | 2001-10-10 | — | — | EP | claimed |
| US-20010027202-A1 | Omega-carboxyaryl substituted disphenyl ureas as raf kinase inhibitors | BAYER HEALTHCARE LLC | 2001-10-04 | — | — | US | claimed |
| US-20010016659-A1 | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors | BAYER HEALTHCARE LLC | 2001-08-23 | — | — | US | claimed |
| US-20010011135-A1 | Omega-carboxyaryl subsituted diphenyl ureas as raf kinase inhibitors | BAYER HEALTHCARE LLC | 2001-08-02 | — | — | US | claimed |
| US-20010011136-A1 | omega-carboxyyaryl substituted diphenyl ureas as raf kinase inhibitors | BAYER HEALTHCARE LLC | 2001-08-02 | — | — | US | claimed |
| WO-2000041698-A1 | φ-CARBOXY ARYL SUBSTITUTED DIPHENYL UREAS AS p38 KINASE INHIBITORS | BAYER CORPORATION (US) | 2000-07-20 | — | — | WO | claimed |
| WO-2000042012-A1 | φ-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS | BAYER CORPORATION (US) | 2000-07-20 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010011135-A1 | Omega-carboxyaryl subsituted diphenyl ureas as raf kinase inhibitors | BRAF, RAF1, ARAF | RAF1 2/4885KDR 611/4885RET 128/4885 |
| US-20210113614-A1 | COMBINATION OF CELLULAR IMMUNOTHERAPY | CD47, IL2RA, IL2 | RAF1 470/4885KDR 648/4885RET 76/4885 |
| US-20010011136-A1 | omega-carboxyyaryl substituted diphenyl ureas as raf kinase inhibitors | BRAF, ARAF, RAF1 | RAF1 3/4885KDR 624/4885RET 170/4885 |
| US-20010034447-A1 | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors | BRAF, RAF1, ARAF | RAF1 2/4885KDR 567/4885RET 182/4885 |
| US-20010016659-A1 | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors | BRAF, RAF1, ARAF | RAF1 2/4885KDR 567/4885RET 182/4885 |
| US-20010027202-A1 | Omega-carboxyaryl substituted disphenyl ureas as raf kinase inhibitors | BRAF, NRAS, ARAF | RAF1 4/4885KDR 487/4885RET 70/4885 |
| US-20020042517-A1 | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors | BRAF, RAF1, ARAF | RAF1 2/4885KDR 567/4885RET 182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.